A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.

ABSTRACT:

Background and objectives

Niacinamide inhibits intestinal sodium/phosphorus transporters and reduces serum phosphorus in open-label studies. A prospective, randomized, double-blind, placebo-controlled crossover trial was performed for assessment of the safety and efficacy of niacinamide.

Design, setting, participants, & measurements

Hemodialysis patients with phosphorus levels > or =5.0 mg/dl were randomly assigned to 8 wk of niacinamide or placebo, titrated from 500 to 1500 mg/d. After a 2-wk washout period, patients switched to 8 wk of the alternative therapy. Vitamin D analogs and calcimimetics were held constant; phosphorus binders were not changed unless safety criteria were met.

Results

Thirty-three patients successfully completed the trial. Serum phosphorus fel

SUBMITTER: Cheng SC 

PROVIDER: S-EPMC2440276 | biostudies-literature | 2008 Jul

REPOSITORIES: biostudies-literature